Novel Therapeutic Options to Optimize Outcomes in Agitation Associated with Dementia Due to Alzheimer’s Disease
Released On
January 7, 2025
Expires On
January 7, 2026
Media Type
Internet
Completion Time
30 minutes
Specialty
Neurology, Psychiatry
Topics
Alzheimer's, Dementia
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC (PQHE), in collaboration with BrightFocus Foundation.
Acknowledgement
This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.
Date of Release/Expiration
This activity was released on January 7, 2025, and is valid until January 7, 2026. Requests for credit must be made no later than January 7, 2026.
Credit Available
- Physicians - maximum of 0.5 AMA PRA Category 1 Credit™
Target Audience
The educational design of this activity addresses the needs of psychiatrists, neurologists, and advanced care practitioners (ACPs) involved in the care of people with Alzheimer’s disease and AAD.
Program Overview
Agitation associated with dementia (AAD) due to Alzheimer’s disease (AD) is one of the most stressful and complex aspects of living with AD, for both those with AAD and their caregivers. Early recognition is crucial to make the most of newly approved therapies for AAD.
In this four-module education, join Dr. George Grossberg, an expert psychiatrist, and Dr. Alireza Atri, an expert neurologist, as they discuss the importance of early diagnosis, available screening tools for clinicians and caregivers, and the latest on effective, timely treatment, including how to effectively implement novel treatments in care. Video clips of caregivers for a people living with AAD will elucidate the challenges of obtaining a diagnosis of AAD, and barriers to treatment access, and communicating with HCPs to highlight gaps in care. The panel will provide strategies that clinicians can utilize in daily practice to overcome these challenges. Case-based modules will also offer practical guidance on applying the latest findings and tools in clinical practice to improve outcomes for people with AAD.
Educational Objectives
After completing this activity, the participant should be better able to:
- Summarize the differential-diagnosis process to accurately identify people with AAD
- Utilize validated screening tools to identify people experiencing signs and symptoms suggestive of AAD
- Review personalized treatment plans for people with AAD, taking into consideration the latest safety and efficacy data on available therapies for AAD
Faculty
Alireza Atri, MD
Chief Medical Officer, Banner Research
Banner Alzheimer’s and Research Institutes (Phoenix, Sun City and Tucson, AZ)
Director of the Banner Sun Health Research Institute (Sun City, AZ).
Lecturer on Neurology, Center for Brain/Mind Medicine and Dept of Neurology, Brigham and Women’s Hospital and Harvard Medical School
George Grossberg, MD
Inaugural Henry & Amelia Nasrallah Endowed Professor
Director, Division of Geriatric Psychiatry
Department of Psychiatry & Behavioral Neuroscience
St Louis University School of Medicine
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ. Global is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Physician Continuing Education
Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Estimated Time to Complete
This activity should take approximately 30 minutes to complete.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.
Hardware/Software Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
The planners and managers at Global Education Group and PlatformQ Health Education, LLC have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Accreditation Support
For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].
Technical Support
For any technical issues or issues with your CME Certificate, please contact Medlive at 877-394-1306 or at [email protected].
Review the Medlive Privacy Policy HERE https://www.medlive.com/privacy-policy